CAPRICORN: A story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI

International Journal of Cardiology

Volumn 78, Issue 2, 2001, Pages 109-113

  Coats, Andrew J S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adrenergic receptor antagonist; Carvedilol; Heart failure; Hospitalisation; Mortality; Randomised controlled trial; Trial design

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG INDICATION; EUROPEAN UNION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; THORAX PAIN; UNITED STATES;

EID: 0035029225     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00437-5     Document Type: Editorial

References (40)

1. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
2. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
5. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)
6. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
7. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
8. Quality of life on treatment with metoprolol in dilated cardiomyopathy: Results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial
9. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment
10. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
11. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
12. MIC trial: Metoprolol in patients with mild to moderate heart failure: Effects on ventricular function and cardiopulmonary exercise testing
13. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial)
14. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: Evidence from the AIRE study
15. Beta-blockers - Again, a lesson to us all, especially the research funding community
16. Clinical trials, treatment guidelines and real life
17. Design of the Beta-Blocker Evaluation Survival Trial (BEST)
18. Incidence and aetiology of heart failure; a population-based study
19. Gender-related differences in modulation of heart rate in patients with congestive heart failure
20. Does gender bias exist in the medical management of heart failure?
21. Design and methodology of the CAPRICORN trial - A randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infraction
22. Consumer involvement in cardiovascular research: Ways to combat bias and secrecy
23. Cardiovascular research in the dock: A case for the defence
24. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties
25. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
26. Effectiveness of low dose captopril versus propranolol therapy in infants with severe congestive failure due to left-to-right shunts
27. The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure
28. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
29. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
30. Beta-blocker therapy in patients after aortic valve replacement for aortic regurgitation
31. Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones
32. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study
33. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure
34. The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy
35. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebo-controlled study
36. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction
37. Effect of beta-blockade on baroreceptor and autonomic function in heart failure
38. Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes
39. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure
40. Heart Failure 99 - The MOXCON story